- Home
- AIRJW vs TGTX Comparison
AIRJW vs TGTX Comparison
Compare AIRJW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIRJW | TGTX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | 17 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.0B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | AIRJW | TGTX |
|---|---|---|
| Price | $0.84 | $31.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $51.60 |
| AVG Volume (30 Days) | 19.1K | ★ 2.4M |
| Earning Date | 03-21-2025 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.07 | 2.78 |
| Revenue | N/A | ★ $531,898,000.00 |
| Revenue This Year | N/A | $87.88 |
| Revenue Next Year | N/A | $47.78 |
| P/E Ratio | ★ $2.05 | $11.39 |
| Revenue Growth | N/A | ★ 100.88 |
| 52 Week Low | $1.11 | $25.28 |
| 52 Week High | $1.32 | $46.48 |
Technical Indicators
Market Signals| Indicator | AIRJW | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 55.99 |
| Support Level | $0.70 | $29.80 |
| Resistance Level | $0.92 | $33.24 |
| Average True Range (ATR) | 0.06 | 1.66 |
| MACD | -0.01 | 0.33 |
| Stochastic Oscillator | 56.00 | 71.18 |
Price Performance
Historical ComparisonAbout AIRJW Montana Technologies Corporation Warrant
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.